Please assess the completion status of the following clinical trial:

Trial Title: The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of presumed autoimmune type 1 diabetes, receiving daily insulin~2. Age 18-\<65 years~3. Duration of T1D ≥ 2 years~4. Random C-peptide \< 0.6 ng/ml~5. Using continuous subcutaneous insulin infusion (CSII; insulin pump) for at least 6 months, with no plans to discontinue pump use during the study~6. Exercises regularly, i.e. ≥30 minutes moderate or more vigorous aerobic activity X ≥3 times/week~7. Body mass index (BMI) \<30 kg/m2~8. Females must meet one of the following criteria:~   * Of childbearing potential and not currently pregnant or lactating, and agrees to use an accepted contraceptive regimen as described in the study procedure manual throughout the entire duration of the study; or~  * Of non-childbearing potential, defined as a female who has had a hysterectomy or tubal ligation, is clinically considered infertile or is in a menopausal state (at least 1 year without menses)~9. In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the investigator is a good candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations~10. Willing to adhere to the protocol requirements for the duration of the study~11. Must be enrolled in the T1D Exchange clinic registry or willing to join the registry~Exclusion Criteria:~1. One or more severe hypoglycemic episodes in the past 12 months (as defined by an episode that required third party assistance for treatment)~2. Active diabetic retinopathy (proliferative diabetic retinopathy or vitreous hemorrhage in past 6 months) that could potentially be worsened by exercise protocol~3. Peripheral neuropathy with insensate feet~4. Cardiovascular autonomic neuropathy with inappropriate heart rate response to exercise~5. Use of non-insulin anti-diabetic medications~6. Use of beta-blockers~7. Use of agents that affect hepatic glucose production such as beta adrenergic agonists, xanthine derivatives~8. Use of Pramlintide~9. Currently following a very low calorie or other weight-loss diet~10. Participation in other studies involving administration of an investigational drug or device within 30 days or 5 half-lives, whichever is longer, before screening for the current study or planning to participate in another such study during participation in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No basal insulin adjustment, no carbohydrate intake (until glucose drops \<70 mg/dL).
- Basal insulin reduction (Type: ACTIVE_COMPARATOR): Basal insulin reduction to 50% five minutes before the start of exercise.
- Glucose Tabs (Type: ACTIVE_COMPARATOR): Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
- G-Pen Mini™ (glucagon injection) (Type: EXPERIMENTAL): Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).

Based on this trial design, predict the completion outcome and termination type (if applicable).